Clinical Trial Update: A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM) [Phase 1]

View source ↗

Summary

This is a Phase 1 open-label study evaluating the safety of intravenously delivered allogeneic neonatal mesenchymal cells (nMSCs) in pediatric and young adult p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy

Drugs mentioned

• neonatal mesenchymal cells (nMSCs) (neonatal mesenchymal cells)

Snippet

Sponsor: Emory University | Conditions: Dilated Cardiomyopathy | Phase 1 | Status: RECRUITING